Attributes for preference of new fast dissolving tablet (FDT) formulation of Ebastine in patients with allergy

被引：0
|
作者：
Roger, A
Fortea, J
Artes, M
Montilla, L
机构：
[1] Ctr Roger Barri Asmol & Allergia, Barcelona, Spain
[2] Labs Almirall SA, Barcelona, Spain
[3] Adelphi Targis SL, Barcelona, Spain
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67208-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A23 / A23
页数：1
相关论文
共 50 条
  • [31] Zolmitriptan 2.5 mg orally disintegrating tablet for acute treatment of migraine: Part II - Patient preference for a new formulation
    Purdy, A
    MacGregor, EA
    Dowson, AJ
    NEUROLOGY, 2001, 56 (08) : A357 - A358
  • [32] Study of the Gastrointestinal Tolerance of a New Tablet Formulation of the Lopinavir/Ritonavir Antiretroviral in HIV-Infected Patients
    Saez de la Fuente, Javier
    Granja, Virginia
    Escobar, Ismael
    Collada de la Fuente, Elena
    Moreno, Victor
    Rubio, Rafael
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 50 (03) : 294 - 298
  • [33] Fast-Dissolving Sublingual Nanofibers of Ondansetron Hydrochloride: Formulation, Physicochemical Characterization, and Clinical Evaluation on Post-cataract Surgery Patients
    Kamranpour, Samira
    Mirzaeei, Shahla
    Daneshgar, Farid
    Najafi, Farid
    PHARMACEUTICAL SCIENCES, 2022, 28 (01) : 101 - 111
  • [34] New Data confirm the Efficacy of the Early-blooming Tablet ITULAZAX® also for Patients with Oak Pollen Allergy
    不详
    ALLERGOLOGIE, 2021, 44 (12) : 974 - 974
  • [35] Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemia
    Viprakasit, Vip
    Hamdy, Mona M. M.
    Hassab, Hoda M. A.
    Sherief, Laila M. M.
    Al-Bagshi, Muneer
    Khattab, Mohammed
    Chuncharunee, Suporn
    Dung, Phu Chi
    Kupesiz, Alphan
    Shekhawat, Ankita
    Sonawane, Yamini
    Perez, Laura Torres
    Slader, Cassandra
    Taher, Ali T. T.
    ANNALS OF HEMATOLOGY, 2023, 102 (08) : 2039 - 2049
  • [36] The preference for controlled-release mesalazine formulation of 2 g-granule sachet in patients already experienced 1 g-tablet
    Moon, W.
    Park, S. J.
    Kim, J. H.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1042 - I1044
  • [37] Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemia
    Vip Viprakasit
    Mona M. Hamdy
    Hoda M. A. Hassab
    Laila M. Sherief
    Muneer Al-Bagshi
    Mohammed Khattab
    Suporn Chuncharunee
    Phu Chi Dung
    Alphan Küpesiz
    Ankita Shekhawat
    Yamini Sonawane
    Laura Torres Perez
    Cassandra Slader
    Ali T. Taher
    Annals of Hematology, 2023, 102 : 2039 - 2049
  • [38] Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients:: a new approach to treatment of incident pain
    Lennernäs, B
    Hedner, T
    Holmberg, M
    Bredenberg, S
    Nyström, C
    Lennernäs, H
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (02) : 249 - 253
  • [39] New tablet formulation of tacrolimus with smaller interindividual variability may become a better treatment option than the conventional capsule formulation in organ transplant patients
    Kim, Yu Kyong
    Kim, Anhye
    Park, Shin Jung
    Lee, Howard
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 2861 - 2869
  • [40] Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients
    Ofotokun I.
    Chuck S.K.
    Schmotzer B.
    O'Neil K.L.
    AIDS Research and Therapy, 6 (1)
12345